Kyodo University To Provide Pharmaceutical Companies iPS Cells
This article was originally published in PharmAsia News
Executive Summary
Effective July 7, Kyodo University will begin providing human and mouse induced pluripotent stem cells to private enterprises such as pharmaceutical companies. For a fee, the university will provide iPS cells made from skin cells induced by three or four genes. The iPS research center at Kyoto University is also available to provide cell culture guidance to companies. The duration of service will be for one year and intellectual property issues will be dealt with between the center and the companies. It is the first time the school will provide such service to the private sector. Kyoto University provided mouse iPS cells to Riken Bioresource Center, a research facility, in March. (Click here for more - Japanese language
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.